RFG Advisory LLC Sells 559 Shares of Danaher Co. (NYSE:DHR)

RFG Advisory LLC lessened its stake in shares of Danaher Co. (NYSE:DHR) by 8.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,416 shares of the conglomerate’s stock after selling 559 shares during the quarter. RFG Advisory LLC’s holdings in Danaher were worth $1,473,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of DHR. FMR LLC boosted its holdings in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Danaher by 3.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares in the last quarter. Fisher Asset Management LLC grew its holdings in shares of Danaher by 2.6% during the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after purchasing an additional 116,299 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after buying an additional 535,254 shares during the period. Finally, Montrusco Bolton Investments Inc. raised its holdings in Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR opened at $245.95 on Friday. Danaher Co. has a one year low of $225.42 and a one year high of $281.70. The company has a market cap of $177.65 billion, a PE ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. The stock has a 50-day moving average of $235.33 and a 200-day moving average of $253.45. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is 20.61%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on DHR shares. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Raymond James decreased their price objective on Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a report on Tuesday, January 21st. Stifel Nicolaus raised their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Royal Bank of Canada reduced their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Citigroup lowered their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.